Etbmed 150mg Tablet contains Erlotinib, a targeted anticancer agent used primarily in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Erlotinib works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a crucial role in the proliferation and survival of cancer cells. By blocking this receptor, Etbmed helps to slow or stop the growth of tumors. This medication is typically prescribed for patients with advanced or metastatic NSCLC who have specific EGFR mutations or as part of combination therapy for pancreatic cancer. Etbmed 150mg is administered orally, usually once daily, and should be taken on an empty stomach to enhance absorption. Common side effects may include rash, diarrhea, loss of appetite, and fatigue, while more serious adverse effects can involve interstitial lung disease and liver toxicity, necessitating close monitoring by a healthcare professional. Patients are advised to avoid excessive sun exposure due to increased photosensitivity and to inform their doctor of any other medications or supplements they are taking to prevent potential interactions. Etbmed 150mg Tablet offers a targeted approach to cancer treatment, improving outcomes and quality of life for many patients.